NO20054071L - Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer. - Google Patents

Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.

Info

Publication number
NO20054071L
NO20054071L NO20054071A NO20054071A NO20054071L NO 20054071 L NO20054071 L NO 20054071L NO 20054071 A NO20054071 A NO 20054071A NO 20054071 A NO20054071 A NO 20054071A NO 20054071 L NO20054071 L NO 20054071L
Authority
NO
Norway
Prior art keywords
polymorphs
protein kinase
kinase inhibitors
pyrrole substituted
pyrrole
Prior art date
Application number
NO20054071A
Other languages
English (en)
Other versions
NO20054071D0 (no
Inventor
Todd P Foster
Changquan Sun
Fusen Han
Michael Hawley
Tom Thamann
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20054071D0 publication Critical patent/NO20054071D0/no
Publication of NO20054071L publication Critical patent/NO20054071L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives polymorfer av den 3-pyrrol-substituerte 2-indolinonforbindelse 5[5-fluor-2-okso-l,2-dihydroindol-(3)-ylidenmetyl]-2,4-dimetyl-l H-pyrrol-3-karboksylsyre-(2-pyrrolidin-l-yletyi)-amid.
NO20054071A 2003-02-24 2005-09-01 Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer. NO20054071L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44886303P 2003-02-24 2003-02-24
US10/776,337 US7452913B2 (en) 2003-02-24 2004-02-12 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
PCT/US2004/005281 WO2004076410A2 (en) 2003-02-24 2004-02-23 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Publications (2)

Publication Number Publication Date
NO20054071D0 NO20054071D0 (no) 2005-09-01
NO20054071L true NO20054071L (no) 2005-10-13

Family

ID=32930498

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054071A NO20054071L (no) 2003-02-24 2005-09-01 Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.

Country Status (14)

Country Link
US (2) US7452913B2 (no)
EP (2) EP1599200A4 (no)
JP (1) JP2006518755A (no)
KR (1) KR20050107588A (no)
AU (1) AU2004215407C1 (no)
BR (1) BRPI0407795A (no)
CA (1) CA2516900A1 (no)
MX (1) MXPA05008959A (no)
NO (1) NO20054071L (no)
NZ (1) NZ541720A (no)
PL (1) PL378570A1 (no)
RU (1) RU2335502C2 (no)
WO (1) WO2004076410A2 (no)
ZA (1) ZA200506370B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
NZ566033A (en) * 2005-09-19 2011-04-29 Pfizer Prod Inc Solid salt forms of a pyrrole substituted 2-indolinone
TWI387019B (zh) * 2007-08-02 2013-02-21 日月光半導體製造股份有限公司 在基材上形成穿導孔之方法
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011110199A1 (en) 2010-03-10 2011-09-15 Synthon B.V. A process for amidation of pyrrole carboxylate compounds
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
MX2017001818A (es) 2014-08-08 2017-05-30 Forsight Vision4 Inc Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
PT1255536E (pt) * 1999-12-22 2006-09-29 Sugen Inc Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
US6339100B1 (en) 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
DE122008000002I1 (de) * 2000-02-15 2008-04-17 Sugen Inc Pyrrol substituierte indolin-2-on protein kinase inhibitoren
TWI270545B (en) 2000-05-24 2007-01-11 Sugen Inc Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002081466A1 (en) 2001-04-09 2002-10-17 Sugen, Inc. Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
BR0307721A (pt) * 2002-02-15 2005-01-25 Upjohn Co Processo para preparação de derivados de indolinona
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
US7452913B2 (en) 2008-11-18
EP1599200A4 (en) 2007-02-07
EP2258699A1 (en) 2010-12-08
RU2335502C2 (ru) 2008-10-10
ZA200506370B (en) 2006-12-27
MXPA05008959A (es) 2005-11-04
HK1086486A1 (en) 2006-09-22
EP1599200A2 (en) 2005-11-30
WO2004076410A3 (en) 2005-03-03
RU2005129743A (ru) 2006-02-10
JP2006518755A (ja) 2006-08-17
CA2516900A1 (en) 2004-09-10
US20090048327A1 (en) 2009-02-19
BRPI0407795A (pt) 2006-02-14
AU2004215407C1 (en) 2009-07-09
WO2004076410A8 (en) 2005-10-20
AU2004215407A1 (en) 2004-09-10
PL378570A1 (pl) 2006-05-02
NZ541720A (en) 2009-02-28
WO2004076410A2 (en) 2004-09-10
NO20054071D0 (no) 2005-09-01
US20040259929A1 (en) 2004-12-23
KR20050107588A (ko) 2005-11-14

Similar Documents

Publication Publication Date Title
IS7147A (is) Kristallaefni, sem innihalda malínsýrusalt N-[2-(díetýlamínó)etýl]-5-[(5-flúóro-2-oxó-3H-indól-3-ýlíðen)metýl]-2,4-dímetýl-1H-pýrról-3-karbóoxamíðs, aðferðir við framleiðslu þess og efnasamsetningar þeirra
CY2008004I2 (el) Πυρρολο υποκατεστημενης 2-ινδολινονης αναστολεις κινασης πρωτεϊνης
EP1954683A4 (en) 2- (PHENYL OR HETEROCYCLYL) -1H-PHENANTHRO (9,10-D) IMIDAZOLE AS MPGES-1 INHIBITORS
BRPI0605921A2 (pt) compostos orgánicos
NO20051337L (no) Indol- eller benzimidazolderivater for modulering av ikB-kinase.
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
NL1029799A1 (nl) Enantiomeer zuivere aminoheteroarylverbindingen als proteïnekinaseremmers.
ATE284885T1 (de) 3-indolyl-4-phenyl-1h-pyrrol-2,5-dion derivate als glycogen synthase kinase 3beta inhibitoren
HRP20130797T1 (en) Condensed imidazolo derivatives for the inhibition of aldosterone synthase and aromatase
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
ATE354573T1 (de) ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
ATE316527T1 (de) Substituierte indolinone als tyrosinkinase inhibitoren
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
NL1029809C2 (nl) Pyrazool-gesubstitueerde aminoheteroarylverbindingen als proteïnekinaseremmers.
NZ596024A (en) Indole compounds
ATE433968T1 (de) Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
TW200616965A (en) Synthesis of n2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents
DE60140368D1 (de) Substitutuierte imidazole als tafia inhibitoren
NO20054071L (no) Polymorfer av pyrrol substituerte 2-indolinon protein kinase inhibitorer.
CY1110771T1 (el) Αλατα και πολυμορφα μιας πυρρολο-υποκατεστημενης ινδολινονικης ενωσης
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
MY157375A (en) Novel crystalline forms of <2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl>-(2-chlorophenyl)-methanone
WO2010010454A3 (en) Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
HRP20050035B1 (hr) Kristalniäśni 2,5-dion-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirol monohidroklorid

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application